Gujarat Themis Biosyn to Acquire MicroBiopharm Japan for ₹1,300 Crore
Gujarat Themis Biosyn will acquire MicroBiopharm Japan for approximately ₹1,300 crore (JPY 21.5 billion). The deal aims to transform GTBL into a CDMO platform, leveraging MBJ's fermentation and biotechnology expertise. MBJ reported FY26 revenues of approximately ₹570 crore (JPY 9.5 billion). The acquisition is expected to close in Q2FY27.
The acquisition of a significant international entity like MBJ for a substantial amount is expected to have a transformative impact on GTBL's business model and market presence.
The acquisition is a strategic move to enhance the company's capabilities and market position, indicating positive future growth prospects.
Gujarat Themis Biosyn Limited (GTBL) has announced the signing of a definitive agreement to acquire 100% equity shareholding of MicroBiopharm Japan Co., Ltd. (MBJ), a Japan-based company with over six decades of experience in fermentation and microbial-based research, development, and manufacturing.
The acquisition, to be executed through a wholly owned special purpose vehicle (SPV) in Japan, is expected to close during Q2FY27. MBJ recorded an estimated revenue of JPY 9.5 billion (approximately ₹570 crore) for FY26. The acquisition cost is approximately JPY 21.5 billion (approximately ₹1,300 crore), expected to be funded through a mix of debt and equity, and is anticipated to be EPS accretive.
This strategic move aims to transform GTBL from a fermentation-led intermediates business into a technology-driven Contract Development Manufacturing Organization (CDMO) platform. MBJ brings complementary capabilities in precision fermentation, proprietary technologies like P450 enzyme library and Plasmid DNA technology, and a portfolio including oncology, immunosuppressants, antibiotics, and peptides. MBJ also offers end-to-end CDMO services in small molecules and biologics.
Dr. Sachin Patel, Managing Director of GTBL, stated that the acquisition is a strategic step towards a next-generation, discovery-led CDMO platform, enhancing their ability to serve global customers. He assured that MBJ's current capabilities, leadership, and employees will be built upon for mutual growth.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.